Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A recent study carried out by UHN's McLaughlin-Rotman Centre for Global Health (MRC) proves that collaboration between health biotech companies and developing countries is a win-win situation. Co-authors Dr. Halla Thorsteinsdóttir and Monali Ray explain why:Q: What are some of the misconceptions of partnerships with developing countries?
One is that collaborating with developing countries won't strengthen Canadian innovation. The opposite is true. Collaboration is heavily based on research and developmental activities that take advantage of each others expertise and strengths. Another misconception is that the knowledge contributions are predominantly made by Canadian firms. Developing countries are not simply at the receiving end of the partnerships. They are active contributors in product development.
Q: It seems obvious that biotech firms can benefit from partnering in terms of market reach and distribution networks. What's in it for developing countries?
Developing countries gain access to expertise relevant for developing new drugs, vaccines and diagnostics. Canadian
firms can also offer experience in product innovation, conducting clinical trials, and have a mature system geared to regulate innovation in this field. We are also close to the US, which has a huge biotech market. Q: What are the top three things to consider when collaborating with a developing country?